Brahm M
Clin Nephrol. 1986 May;25(5):231-5.
Se-aluminum was measured in a study group and a control group of undialyzed chronic uremic patients having a similar reduction of kidney function (median GFR 7 [range 5-15] ml/min/1.73 m2). Se-aluminum values (0-11, median 3, micrograms/l) in the control group (31 patients) receiving no treatment with aluminum-containing phosphate-binding gels, were all below the upper normal range (17 micrograms/l). The study group (28 patients) was treated with oral Al(OH)3 for 0.5-18 (median 6) months. Se-aluminum in this group was 17-230 (median 35) micrograms/l. It is concluded that se-aluminum increases in undialyzed chronic uremic patients ingesting aluminum-containing antacids. The study suggests that se-aluminum varies with the daily dose of aluminum hydroxide, and that se-aluminum in particular increases when the daily doses are more than 3 g Al(OH)3.
在一组未透析的慢性尿毒症患者和一组肾功能下降程度相似（中位肾小球滤过率[GFR]为7[范围5 - 15]ml/分钟/1.73平方米）的对照组中测量了血清铝。在未接受含铝磷酸盐结合凝胶治疗的对照组（31例患者）中，血清铝值（0 - 11，中位值3，微克/升）均低于正常上限（17微克/升）。研究组（28例患者）接受口服氢氧化铝治疗0.5 - 18（中位值6）个月。该组的血清铝为17 - 230（中位值35）微克/升。得出的结论是，摄入含铝抗酸剂的未透析慢性尿毒症患者血清铝会升高。该研究表明，血清铝随氢氧化铝的每日剂量而变化，特别是当每日剂量超过3克氢氧化铝时血清铝会升高。
